PubMed:32472191 JSONTXT

{"project":"LitCovid-OGER-BB","denotations":[{"id":"T1","span":{"begin":60,"end":68},"obj":"SP_7"},{"id":"T2","span":{"begin":120,"end":131},"obj":"NCBITaxon:11118"},{"id":"T3","span":{"begin":146,"end":154},"obj":"SP_7"},{"id":"T4","span":{"begin":161,"end":165},"obj":"UBERON:0000104"},{"id":"T5","span":{"begin":202,"end":249},"obj":"SP_7"},{"id":"T6","span":{"begin":215,"end":226},"obj":"UBERON:0001004"},{"id":"T7","span":{"begin":251,"end":261},"obj":"SP_7"},{"id":"T8","span":{"begin":263,"end":268},"obj":"NCBITaxon:10239"},{"id":"T9","span":{"begin":326,"end":334},"obj":"SP_7"},{"id":"T10","span":{"begin":400,"end":408},"obj":"SP_7"},{"id":"T11","span":{"begin":501,"end":507},"obj":"NCBITaxon:9606"},{"id":"T12","span":{"begin":539,"end":547},"obj":"SP_7"},{"id":"T13","span":{"begin":630,"end":638},"obj":"UBERON:0003126"},{"id":"T14","span":{"begin":684,"end":689},"obj":"GO:0016265"},{"id":"T15","span":{"begin":876,"end":879},"obj":"UBERON:0005942"},{"id":"T16","span":{"begin":1355,"end":1359},"obj":"GO:0016265"},{"id":"T17","span":{"begin":1560,"end":1565},"obj":"PR:000013883"},{"id":"T18","span":{"begin":1645,"end":1650},"obj":"PR:000008856"},{"id":"T19","span":{"begin":1678,"end":1685},"obj":"CHEBI:17234"},{"id":"T20","span":{"begin":1678,"end":1685},"obj":"CHEBI:17234"},{"id":"T21","span":{"begin":1915,"end":1925},"obj":"CL:0000542"},{"id":"T22","span":{"begin":1956,"end":1974},"obj":"PR:000005897"},{"id":"T23","span":{"begin":2325,"end":2330},"obj":"GO:0016265"},{"id":"T24","span":{"begin":2373,"end":2379},"obj":"NCBITaxon:9606"},{"id":"T25","span":{"begin":2411,"end":2419},"obj":"SP_7"},{"id":"T26","span":{"begin":2444,"end":2451},"obj":"CHEBI:17234"},{"id":"T27","span":{"begin":2444,"end":2451},"obj":"CHEBI:17234"},{"id":"T28","span":{"begin":2444,"end":2459},"obj":"GO:0042593"},{"id":"T29","span":{"begin":2510,"end":2518},"obj":"UBERON:0003126"},{"id":"T30","span":{"begin":2537,"end":2542},"obj":"GO:0016265"}],"namespaces":[{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"}],"text":"Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.\nAIMS/HYPOTHESIS: Coronavirus disease-2019 (COVID-19) is a life-threatening infection caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus. Diabetes has rapidly emerged as a major comorbidity for COVID-19 severity. However, the phenotypic characteristics of diabetes in COVID-19 patients are unknown.\nMETHODS: We conducted a nationwide multicentre observational study in people with diabetes hospitalised for COVID-19 in 53 French centres in the period 10-31 March 2020. The primary outcome combined tracheal intubation for mechanical ventilation and/or death within 7 days of admission. Age- and sex-adjusted multivariable logistic regressions were performed to assess the prognostic value of clinical and biological features with the endpoint. ORs are reported for a 1 SD increase after standardisation.\nRESULTS: The current analysis focused on 1317 participants: 64.9% men, mean age 69.8 ± 13.0 years, median BMI 28.4 (25th-75th percentile: 25.0-32.7) kg/m2; with a predominance of type 2 diabetes (88.5%). Microvascular and macrovascular diabetic complications were found in 46.8% and 40.8% of cases, respectively. The primary outcome was encountered in 29.0% (95% CI 26.6, 31.5) of participants, while 10.6% (9.0, 12.4) died and 18.0% (16.0, 20.2) were discharged on day 7. In univariate analysis, characteristics prior to admission significantly associated with the primary outcome were sex, BMI and previous treatment with renin-angiotensin-aldosterone system (RAAS) blockers, but not age, type of diabetes, HbA1c, diabetic complications or glucose-lowering therapies. In multivariable analyses with covariates prior to admission, only BMI remained positively associated with the primary outcome (OR 1.28 [1.10, 1.47]). On admission, dyspnoea (OR 2.10 [1.31, 3.35]), as well as lymphocyte count (OR 0.67 [0.50, 0.88]), C-reactive protein (OR 1.93 [1.43, 2.59]) and AST (OR 2.23 [1.70, 2.93]) levels were independent predictors of the primary outcome. Finally, age (OR 2.48 [1.74, 3.53]), treated obstructive sleep apnoea (OR 2.80 [1.46, 5.38]), and microvascular (OR 2.14 [1.16, 3.94]) and macrovascular complications (OR 2.54 [1.44, 4.50]) were independently associated with the risk of death on day 7.\nCONCLUSIONS/INTERPRETATIONS: In people with diabetes hospitalised for COVID-19, BMI, but not long-term glucose control, was positively and independently associated with tracheal intubation and/or death within 7 days.\nTRIAL REGISTRATION: clinicaltrials.gov NCT04324736."}